Results 241 to 250 of about 231,111 (314)

Liposomal Nanoconfinement Enables Type I Photodynamic Conversion for Synergistic Cancer Photothermal‐Immunotherapy

Advanced Science, EarlyView.
Liposomal nanoconfinement converts the hemicyanine photosensitizer RhM from Type‐II to Type‐I photodynamic therapy (PDT) while enhancing photothermal therapy (PTT). The RhM‐R837@Lip nanoassembly efficiently generates superoxide (O2•−) and hydroxyl radicals (•OH) to kill tumor cells and achieve tumor ablation.
Minglu Zhang, Shanshan Liang, Meng Wang, Tingfeng Zhang, Jinke Liu, Yuyuan Peng, Hao Fang, Lingna Zheng, Xiao He, Meng Wang, Luling Wu, Tony D. James, Wei Zhao, Bing Wang, Weiyue Feng   +14 more
wiley   +1 more source

Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study. [PDF]

Oncol Lett
Gong Z, Kang S, Bai C, Li Y, Yu X, Shang K, Song Y, Cheng F, Wang J.   +8 more
europepmc   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

Advanced Science, EarlyView.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang, Shiyao Song, Xinhua Zhang, Jialing Gao, Ruihan Pu, Jiatong Dai, Xiaoxue Wu, Lulu Chen, Qinghai Li, Xiaoting Liu, Qi Zhou, Mei Song, Weiling He   +12 more
wiley   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial. [PDF]

ESMO Gastrointest Oncol
Tintelnot J, Gorgulho J, Al-Batran SE, Arnold D, Reinacher-Schick A, Kasper S, Prager G, Goetze T, Boston R, Cruz MS, Dierks F, Stein A.   +11 more
europepmc   +1 more source

Unveiling trends and clinical progress of immunotherapy for endometrial cancer: a scientometric and clinical trial landscape analysis. [PDF]

Front Immunol
Liu R, Shan W, Hu Z, Wang H, Wang Z, Yang L, Guo R.   +6 more
europepmc   +1 more source

DUSP1: Triple-Negative Breast Cancer and Therapeutic Potential. [PDF]

Curr Oncol
Niture S, Thotala D, Jaboin J, Seneviratne D.   +3 more
europepmc   +1 more source

Precision Delivery of Active Compounds from Edible and Medicinal Plants via Gut Microbiota Targeting: A New Paradigm for Cancer Immunotherapy. [PDF]

Nutrients
Peng L, Wang L, Zhao Y, Yu P, Yang H.
europepmc   +1 more source

Multidisciplinary Treatment With Hepatic Arterial Infusion Chemotherapy, Radiotherapy, and Immunotherapy for Advanced Hepatocellular Carcinoma With Major Vascular Invasion: Prospective Registry Protocol.

JMIR Res Protoc
Doi Y, Aikata H, Kosaka Y, Nakahara T, Kodama M, Hieda M, Hashimoto M, Nakahara H, Takahashi I, Kakizawa H, Mori N, Tsuji K, Imano N, Murakami Y, Sueda S, Kawaoka T, Tsuge M, Oka S.   +17 more
europepmc   +1 more source